Overview
Tesamorelin is distinguished within this category by an approved indication and comparatively strong clinical evidence for visceral fat reduction.
peptide Growth Hormone AxisMetabolic & Weight Management
A stabilized GHRH analog with one of the strongest evidence bases in the growth-hormone-secretagogue category. FDA-approved (Egrifta) for reduction of visceral adipose tissue in HIV-associated lipodystrophy.
Egrifta · brand TH9507 · other GHRH analog · other
Synonyms drive on-site search and are used to index ingested research papers and tweets to this page.
FDA-approved for a specific indication. This page summarizes public information and commentary and is not medical advice.
No structured protocols recorded.
Tesamorelin is distinguished within this category by an approved indication and comparatively strong clinical evidence for visceral fat reduction.